Invivyd (IVVD) FCF Margin (2024 - 2025)
Invivyd posted quarterly FCF Margin of 89.82% for Q4 2025, up 18229.0% year-on-year from N/an in Q4 2024, and down 42.94% on a QoQ basis from 62.84% in Q3 2025.
Invivyd (IVVD) has 2 years of FCF Margin data on file, last reported at 89.82% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 18229.0% year-over-year to 89.82%; the trailing twelve-month figure through Dec 2025 stood at 109.1% (up 56309.0% YoY), and the FY2025 full-year result was 109.1%, up 56309.0% from the prior year.
- FCF Margin for Q4 2025 stood at 89.82%, down from 62.84% in the prior quarter.
- Across five years, FCF Margin topped out at 62.84% in Q3 2025 and bottomed at 1837.41% in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -89.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -89.82% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | -112.95% |
| Mar 31, 2025 | -188.19% |
| Dec 31, 2024 | -272.11% |
| Sep 30, 2024 | -441.65% |
| Jun 30, 2024 | -1,837.41% |